Core Insights - 麦澜德 is focusing on the development and commercialization of non-invasive brain-computer interface (BCI) technology, integrating it with existing technologies and clinical scenarios [1] Group 1: Clinical Directions and Technology Development - The company has developed a closed-loop system for cognitive function intervention, which includes four modules: emotional recognition, emotional interaction, cognitive assessment, and cognitive intervention, currently in multi-center clinical validation [2] - In the field of motor function rehabilitation, 麦澜德 has innovatively combined soft exoskeleton hand functions with EEG devices to create a brain-machine hand training system, showing preliminary effectiveness superior to traditional interventions [2] - For mental and psychosomatic disease regulation, the company is developing a multi-modal brain physiological signal monitoring platform in collaboration with Zhejiang University and other institutions, aiming to create portable products for monitoring brain states [2] Group 2: Technical Advantages and Ecosystem - 麦澜德's core advantages lie in three areas: multi-modal BCI technology for precise screening and personalized treatment, central-peripheral closed-loop technology with early multi-center clinical trials, and breakthroughs in cognitive impairment and emotional interaction [3] - The company has established a collaborative ecosystem involving universities, hospitals, and enterprises, ensuring that research and development align with clinical needs and facilitating resource sharing [3] Group 3: Market Promotion and Competitive Landscape - 麦澜德 has initiated preliminary cooperation with several hospitals in Jiangsu Province and southwestern regions, with some devices already in use at leading hospitals [4] - The competitive landscape in the BCI field is dominated by non-invasive companies, where the speed of obtaining registration certificates and market promotion capabilities are key factors [4] - The company aims to maintain its competitive edge by focusing on core technology research and clinical transformation [4]